04:38 PM EST, 03/03/2025 (MT Newswires) -- ADMA Biologics ( ADMA ) reported Q4 earnings Monday of $0.46 per diluted share, compared with a loss of $0.08 a year earlier.

Three analysts polled by FactSet expected $0.15.

Revenue in the three months ended Dec. 31 rose to $117.5 million from $73.9 million a year earlier.

Three analysts surveyed by FactSet expected $112.8 million.

The company boosted its 2025 revenue forecast to $490 million from $465 million and forecast 2026 revenue of $605 million.

Three analysts polled by FactSet expect revenue of $479.2 million in 2025 and $599 million in 2026.

The company's shares rose 6.2% in after-hours trading.